Aug 11,2021 01:50 PM
Alkem Lab and Natco Pharma gained over 2%. Fortis was also trading 1% higher.
Dr. Lal PathLabs to announce Quarterly Result Jul 23,2021
|Resolution Type||Description Of Resolution||IiAS Recommendation|
|Name||LTP||PE||Mar Cap||NP Qtr||Div. Yld||Sales Qtr||BV|
|Apollo Hospitals Enterprise Ltd||4,911.00||170.28||70,440.82||150.04||0.06||2,994.71||361.76|
|Max Healthcare Institute Ltd||369.45||250.55||35,334.27||87.92||0.00||500.21||61.49|
|Dr Lal Pathlabs Ltd||4,001.70||87.98||32,960.40||123.30||0.51||564.90||148.43|
|Fortis Healthcare Ltd||265.45||0.00||20,127.18||-1.73||0.00||203.52||117.64|
|Metropolis Healthcare Ltd||3,052.00||64.58||15,712.81||59.52||0.26||264.10||138.54|
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Dr. Lal PathLabs has built a national, hub and ... More
Reports by dr-lal-pathlabs-ltd-share-price
Sep 22, 2021 10:39 AM
The company’s consolidated revenue stood at Rs292.50cr, up 11.34% yoy but down 7.87% qoq.
30 Jul 2021
18 Aug 2021
Dr. Lal PathLabs Ltd has informed BSE that the Board of Directors of the Company at its meeting held... More
30 Jul 2021
23 Jul 2021
Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is sc... More
29 Jul 2021
21 May 2021
Convening of 27th Annual General Meeting (AGM) of the Company on Thursday July 29, 2021 through Vide... More